Literature DB >> 17426930

Typical phenotypic spectrum of velocardiofacial syndrome occurs independently of deletion size in chromosome 22q11.2.

Paula Sandrin-Garcia1, Dagma V M Abramides, Lúcia R Martelli, Ester S Ramos, Antônio Richieri-Costa, Geraldo A S Passos.   

Abstract

Velocardiofacial syndrome (VCFS) is a relatively common developmental disorder characterized by craniofacial anomalies and conotruncal heart defects. Many VCFS patients present hemizygous deletions on part of chromosome 22q11.2; suggestive that haploinsufficiency in this region is responsible for this etiology. Most 22q11.2 deletions occur sporadically, although in some cases the deletion may be transmitted. A total of 29 VCFS patients and their parents were genotyped using six consecutive polymorphic markers (STS) of the chromosome 22q11.2: D22S420, D22S941, D22S264, D22S306, D22S425, and D22S257. The results revealed that 72% (21/29) of the patients harbored a deletion involving the polymorphic markers D22S420, D22S941, and/or D22S264. Haplotype analysis showed that among the patients studied, the deletions were either of maternal or paternal origin. Our findings demonstrated that independently of their size, any deletion occurring in the VCFS critical region is enough to confer the patient phenotype.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17426930     DOI: 10.1007/s11010-007-9450-5

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  30 in total

1.  TBX1 is responsible for cardiovascular defects in velo-cardio-facial/DiGeorge syndrome.

Authors:  S Merscher; B Funke; J A Epstein; J Heyer; A Puech; M M Lu; R J Xavier; M B Demay; R G Russell; S Factor; K Tokooya; B S Jore; M Lopez; R K Pandita; M Lia; D Carrion; H Xu; H Schorle; J B Kobler; P Scambler; A Wynshaw-Boris; A I Skoultchi; B E Morrow; R Kucherlapati
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

2.  Low-copy repeats mediate the common 3-Mb deletion in patients with velo-cardio-facial syndrome.

Authors:  L Edelmann; R K Pandita; B E Morrow
Journal:  Am J Hum Genet       Date:  1999-04       Impact factor: 11.025

Review 3.  The 22q11.2 deletion syndrome.

Authors:  B S Emanuel; D McDonald-McGinn; S C Saitta; E H Zackai
Journal:  Adv Pediatr       Date:  2001

Review 4.  Velo-cardio-facial syndrome: a distinctive behavioral phenotype.

Authors:  R J Shprintzen
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2000

5.  Full spectrum of malformations in velo-cardio-facial syndrome/DiGeorge syndrome mouse models by altering Tbx1 dosage.

Authors:  Jun Liao; Lazaros Kochilas; Sonja Nowotschin; Jelena S Arnold; Vimla S Aggarwal; Jonathan A Epstein; M Christian Brown; Joe Adams; Bernice E Morrow
Journal:  Hum Mol Genet       Date:  2004-06-09       Impact factor: 6.150

Review 6.  Velocardiofacial (Shprintzen) syndrome: an important syndrome for the dysmorphologist to recognise.

Authors:  A H Lipson; D Yuille; M Angel; P G Thompson; J G Vandervoord; E J Beckenham
Journal:  J Med Genet       Date:  1991-09       Impact factor: 6.318

7.  Molecular definition of the 22q11 deletions in velo-cardio-facial syndrome.

Authors:  B Morrow; R Goldberg; C Carlson; R Das Gupta; H Sirotkin; J Collins; I Dunham; H O'Donnell; P Scambler; R Shprintzen
Journal:  Am J Hum Genet       Date:  1995-06       Impact factor: 11.025

8.  A new syndrome involving cleft palate, cardiac anomalies, typical facies, and learning disabilities: velo-cardio-facial syndrome.

Authors:  R J Shprintzen; R B Goldberg; M L Lewin; E J Sidoti; M D Berkman; R V Argamaso; D Young
Journal:  Cleft Palate J       Date:  1978-01

9.  Isolation of a gene expressed during early embryogenesis from the region of 22q11 commonly deleted in DiGeorge syndrome.

Authors:  S Halford; D I Wilson; S C Daw; C Roberts; R Wadey; S Kamath; A Wickremasinghe; J Burn; J Goodship; M G Mattei
Journal:  Hum Mol Genet       Date:  1993-10       Impact factor: 6.150

10.  Phenotype of the 22q11.2 deletion in individuals identified through an affected relative: cast a wide FISHing net!

Authors:  D M McDonald-McGinn; M K Tonnesen; A Laufer-Cahana; B Finucane; D A Driscoll; B S Emanuel; E H Zackai
Journal:  Genet Med       Date:  2001 Jan-Feb       Impact factor: 8.822

View more
  10 in total

1.  Copy-Number Variation of the Glucose Transporter Gene SLC2A3 and Congenital Heart Defects in the 22q11.2 Deletion Syndrome.

Authors:  Elisabeth E Mlynarski; Molly B Sheridan; Michael Xie; Tingwei Guo; Silvia E Racedo; Donna M McDonald-McGinn; Xiaowu Gai; Eva W C Chow; Jacob Vorstman; Ann Swillen; Koen Devriendt; Jeroen Breckpot; Maria Cristina Digilio; Bruno Marino; Bruno Dallapiccola; Nicole Philip; Tony J Simon; Amy E Roberts; Małgorzata Piotrowicz; Carrie E Bearden; Stephan Eliez; Doron Gothelf; Karlene Coleman; Wendy R Kates; Marcella Devoto; Elaine Zackai; Damian Heine-Suñer; Tamim H Shaikh; Anne S Bassett; Elizabeth Goldmuntz; Bernice E Morrow; Beverly S Emanuel
Journal:  Am J Hum Genet       Date:  2015-04-16       Impact factor: 11.025

2.  Defining new guidelines for screening the 22q11.2 deletion based on a clinical and dysmorphologic evaluation of 194 individuals and review of the literature.

Authors:  Fabíola P Monteiro; Társis P Vieira; Ilária C Sgardioli; Miriam C Molck; Ana Paula Damiano; Josiane Souza; Isabella L Monlleó; Marshall I B Fontes; Agnes C Fett-Conte; Têmis M Félix; Gabriela F Leal; Erlane M Ribeiro; Claudio E M Banzato; Clarissa de R Dantas; Iscia Lopes-Cendes; Vera Lúcia Gil-da-Silva-Lopes
Journal:  Eur J Pediatr       Date:  2013-02-26       Impact factor: 3.183

3.  Rare copy number variants and congenital heart defects in the 22q11.2 deletion syndrome.

Authors:  Elisabeth E Mlynarski; Michael Xie; Deanne Taylor; Molly B Sheridan; Tingwei Guo; Silvia E Racedo; Donna M McDonald-McGinn; Eva W C Chow; Jacob Vorstman; Ann Swillen; Koen Devriendt; Jeroen Breckpot; Maria Cristina Digilio; Bruno Marino; Bruno Dallapiccola; Nicole Philip; Tony J Simon; Amy E Roberts; Małgorzata Piotrowicz; Carrie E Bearden; Stephan Eliez; Doron Gothelf; Karlene Coleman; Wendy R Kates; Marcella Devoto; Elaine Zackai; Damian Heine-Suñer; Elizabeth Goldmuntz; Anne S Bassett; Bernice E Morrow; Beverly S Emanuel
Journal:  Hum Genet       Date:  2016-01-07       Impact factor: 4.132

4.  Clinical applications of schizophrenia genetics: genetic diagnosis, risk, and counseling in the molecular era.

Authors:  Gregory Costain; Anne S Bassett
Journal:  Appl Clin Genet       Date:  2012-02-20

5.  Chromosome 22q11.2 microdeletion in monozygotic twins with discordant phenotype and deletion size.

Authors:  Ashutosh Halder; Manish Jain; Isha Chaudhary; Binuja Varma
Journal:  Mol Cytogenet       Date:  2012-03-13       Impact factor: 2.009

6.  Partial microduplication in the histone acetyltransferase complex member KANSL1 is associated with congenital heart defects in 22q11.2 microdeletion syndrome patients.

Authors:  Luis E León; Felipe Benavides; Karena Espinoza; Cecilia Vial; Patricia Alvarez; Mirta Palomares; Guillermo Lay-Son; Macarena Miranda; Gabriela M Repetto
Journal:  Sci Rep       Date:  2017-05-11       Impact factor: 4.379

7.  Sex-specific recombination patterns predict parent of origin for recurrent genomic disorders.

Authors:  Trenell J Mosley; H Richard Johnston; David J Cutler; Michael E Zwick; Jennifer G Mulle
Journal:  BMC Med Genomics       Date:  2021-06-09       Impact factor: 3.063

8.  Genetics and management of the patient with orofacial cleft.

Authors:  Luciano Abreu Brito; Joanna Goes Castro Meira; Gerson Shigeru Kobayashi; Maria Rita Passos-Bueno
Journal:  Plast Surg Int       Date:  2012-11-01

9.  Characteristic face: a key indicator for direct diagnosis of 22q11.2 deletions in Chinese velocardiofacial syndrome patients.

Authors:  Dandan Wu; Yang Chen; Chen Xu; Ke Wang; Huijun Wang; Fengyun Zheng; Duan Ma; Guomin Wang
Journal:  PLoS One       Date:  2013-01-16       Impact factor: 3.240

Review 10.  Consequences of 22q11.2 Microdeletion on the Genome, Individual and Population Levels.

Authors:  Małgorzata Karbarz
Journal:  Genes (Basel)       Date:  2020-08-22       Impact factor: 4.096

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.